This Article Full Text Full Text (PDF) All Versions of this Article: 34/7/1730    most recent 01.STR.0000078658.52316.E8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bereczki, D. Articles by Fekete, I. Search for Related Content PubMed PubMed Citation Articles by Bereczki, D. Articles by Fekete, I. Related Collections Acute Cerebral Hemorrhage Acute Cerebral Infarction Other Stroke Treatment - Medical

(Stroke. 2003;34:1730.)
© 2003 American Heart Association, Inc.

Original Contributions

Mannitol Use in Acute Stroke

Case Fatality at 30 Days and 1 Year

Dániel Bereczki, MD, PhD, DHAS; László Mihálka, MD, PhD; Szabolcs Szatmári, MD, DSci; Klára Fekete, MD; David Di Cesar, MD; Béla Fülesdi, MD, PhD; László Csiba, MD, PhD, DHAS István Fekete, MD, PhD

From the Department of Neurology (D.B., K.F., D.D.C., B.F., L.C., I.F.), University of Debrecen, Debrecen, Hungary; the Department of Neurology (L.M.), University of Uzhgorod, Uzhgorod, Ukraine; and the Department of Neurology (S.S.), University of Targu Mures, Targu Mures, Romania.

Address correspondence to Dr Dániel Bereczki, Department of Neurology, Health Science and Medical Center, University of Debrecen, Debrecen, Nagyerdei krt. 98, H-4012, Hungary. E-mail bereczki{at}jaguar.dote.hu

Background and Purpose— Mannitol is used worldwide to treat acute stroke, although its efficacy and safety have not been proven by randomized trials.

Methods— In a tricenter, prospective study, we analyzed the 30-day and 1-year case fatality with respect to mannitol treatment status in 805 patients consecutively admitted within 72 hours of stroke onset. Confounding factors were compared between treated and nontreated patients.

Results— Two thirds of the patients received intravenous mannitol as part of their routine treatment (mean dose, 47±22 g/d; mean duration, 6±3 days). The case fatality was 25% versus 16% (P=0.006) at 30 days and 38% versus 25% (P<0.001) at 1 year in the-mannitol treated and nontreated groups, respectively. Mannitol treatment effect was adjusted for age, stroke severity, fever in the first 3 days, and aspirin treatment (for ischemic strokes) in logistic regression models. Depending on the factors entered into the model, either no effect or harm could be attributed to mannitol. When the analysis was restricted to those admitted within 24 hours (n=568), case fatality differed significantly only at 1 year (35% in treated and 26% in nontreated patients, P=0.044). Although the prognostic scores of the Scandinavian Neurological Stroke Scale were similar in treated and nontreated patients, both in ischemic and hemorrhagic strokes, the patient groups differed in several factors that might also have influenced survival.

Conclusions— Based on the results of this study, no recommendations can be made on the use of mannitol in acute stroke, and properly randomized, controlled trials should be performed to come to a final conclusion.

Key Words: mannitol • mortality • stroke, acute • stroke management

This article has been cited by other articles:

				E.S. Prakash Is the Use of Hypertonic Mannitol Appropriate in the Management of Intracerebral Hemorrhage? Stroke, May 1, 2008; 39(5): e85 - e85. [Full Text] [PDF]

				D. Bereczki, M. Liu, G. F. do Prado, and I. Fekete Response to Letter by Prakash Stroke, May 1, 2008; 39(5): e86 - e87. [Full Text] [PDF]

				J. Bardutzky and S. Schwab Antiedema Therapy in Ischemic Stroke Stroke, November 1, 2007; 38(11): 3084 - 3094. [Abstract] [Full Text] [PDF]

				NINDS ICH Workshop Participants Priorities for Clinical Research in Intracerebral Hemorrhage: Report From a National Institute of Neurological Disorders and Stroke Workshop Stroke, March 1, 2005; 36(3): e23 - e41. [Abstract] [Full Text] [PDF]